Endometrial carcinoma in young women taking oral contraceptive agents.
The first 21 cases recorded in the Registry for Endometrial Carcinoma in Young Women Taking Oral Contraceptive Agents are reported. We have found no other such cases in the literature, and indeed several authors have stated that these agents, because of their predominantly progestional action, would be expected to be protective against this disease. In 8 of the 21 patients, factors were present which militated against a close relation between oral contraceptives and carcinoma, and 5 of these 8 patients had taken only or predominantly combined agents. On the other hand, 11 of the remaining 13 patients took sequential agents, a ratio directly opposite that of the usage of combined and sequential agents in the American population. The possible reasons for the excess of sequential agents, chiefly Oracon, are discussed, and directions for future study are suggested.
D000230:Adenocarcinoma / Q000139:chemically induced*; D000328:Adult; D002294:Carcinoma, Squamous Cell / Q000139:chemically induced*; D003276:Contraceptives, Oral / Q000009:adverse effects*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects; D003279:Contraceptives, Oral, Sequential / Q000009:adverse effects; D004116:Dimethisterone / Q000009:adverse effects; D004997:Ethinyl Estradiol / Q000009:adverse effects; D005260:Female; D006801:Humans; D009362:Neoplasm Metastasis; D014594:Uterine Neoplasms
D003276:Contraceptives, Oral; D003277:Contraceptives, Oral, Combined; D003279:Contraceptives, Oral, Sequential; D004997:Ethinyl Estradiol; C011523:Oracon; D004116:Dimethisterone